Synthesis, Conformational Analysis and in vivo Assays of an Anti-cancer Vaccine that features an Unnatural Antigen based on a sp2-Iminosugar Fragment

Iris A. Bermejo,a Claudio D. Navo, ORCID logo ab Jorge Castro-López,c Ana Guerreiro,d Ester Jiménez-Moreno,a Elena M. Sánchez Fernández,e Fayna García-Martín, ORCID logo f Hiroshi Hinou,f Shin-Ichiro Nishimura, ORCID logo f José M. García Fernández, ORCID logo g Carmen Ortiz Mellet, ORCID logo e Alberto Avenoza,a Jesús H. Busto,a Gonçalo J. L. Bernardes, ORCID logo dh Ramón Hurtado-Guerrero,cij Jesús M. Peregrina ORCID logo *a and Francisco Corzana ORCID logo *a. Synthesis, Conformational Analysis and in vivo Assays of an Anti-cancer Vaccine that features an Unnatural Antigen based on a sp2-Iminosugar Fragment Chemical Science 2020 | journal-article DOI: 10.1039/c9sc06334j

The Tn antigen (GalNAc-α-1-O-Thr/Ser) is a well-known tumor-associated carbohydrate determinant. The use of glycopeptides that incorporate this structure has become a significant and promising niche of research owing to their potential use as anticancer vaccines. Herein, the conformational preferences of a glycopeptide with an unnatural Tn antigen, characterized by a threonine decorated with an sp2-iminosugar-type α-GalNAc mimic, have been studied both in solution, by combining NMR spectroscopy and molecular dynamics simulations, and in the solid state bound to an anti-mucin-1 (MUC1) antibody, by X-ray crystallography. The Tn surrogate can mimic the main conformer sampled by the natural antigen in solution and exhibits high affinity towards anti-MUC1 antibodies. Encouraged by these data, a cancer vaccine candidate based on this unnatural glycopeptide and conjugated to the carrier protein Keyhole Limpet Hemocyanin (KLH) has been prepared and tested in mice. Significantly, the experiments in vivo have proved that this vaccine elicits higher levels of specific anti-MUC1 IgG antibodies than the analog that bears the natural Tn antigen and that the elicited antibodies recognize human breast cancer cells with high selectivity. Altogether, we compile evidence to confirm that the presentation of the antigen, both in solution and in the bound state, plays a critical role in the efficacy of the designed cancer vaccines. Moreover, the outcomes derived from this vaccine prove that there is room for exploring further adjustments at the carbohydrate level that could contribute to designing more efficient cancer vaccines.

Impact factor: 
9,56